![]() |
市場調查報告書
商品編碼
1679249
睡眠呼吸中止症口腔器具市場預測至 2030 年:按產品類型、性別、年齡層、最終用戶和地區進行的全球分析Sleep Apnea Oral Appliances Market Forecasts to 2030 - Global Analysis By Product, Type, Gender, Age Group, End User and By Geography |
根據 Stratistics MRC 的數據,全球睡眠呼吸中止口腔器具市場預計在 2024 年達到 8.5495 億美元,到 2030 年將達到 23.4341 億美元,預測期內的複合年成長率為 18.3%。
睡眠呼吸中止症口腔器具是自訂的牙科設備,透過重新定位下顎和舌頭來保持睡眠期間氣道暢通,從而治療阻塞型睡眠呼吸中止症(OSA)。這些裝置有時被稱為舌固定裝置(TRD)或下顎前移裝置(MAD),它們可以改善整體呼吸模式、減少打鼾並減少氣道崩壞。患有輕度至中度 OSA 或難以接受 CPAP 治療的患者通常選擇 TRD 作為 CPAP 治療的非侵入性治療方法。
根據《臨床睡眠醫學雜誌》發表的一項研究,口腔器械治療(OAT)顯著降低了呼吸中止低通氣指數(AHI),平均每小時降低了12次,改善了阻塞型睡眠呼吸中止症(OSA)患者的睡眠品質。
睡眠呼吸中止症盛行率不斷上升
睡眠呼吸中止症口腔器具市場的成長很大程度上受到睡眠呼吸暫停,尤其是阻塞型睡眠呼吸中止症(OSA)盛行率不斷上升的推動。 OSA 是由肥胖率上升、久坐的生活方式、吸煙、飲酒和人口老化等因素造成的。此外,研究表明,大量睡眠呼吸中止症病例未被診斷出來,這可能導致嚴重的健康併發症,如糖尿病、心血管疾病和認知障礙。隨著世界各地的醫療保健系統越來越重視睡眠障礙的早期發現和治療,作為治療輕度至中度 OSA 的實用有效方法,口腔器具的需求預計會增加。
對嚴重睡眠呼吸中止症的療效有限
口腔器具在治療嚴重阻塞型睡眠呼吸中止症(OSA)的限制是限制此類設備市場的主要因素之一。對於輕度至中度病例,通常建議使用口腔器具,但在嚴重病例中,其有效性會急劇下降,而持續性陽壓呼吸器(CPAP) 治療仍是黃金標準。此外,口腔器具可能不足以維持嚴重 OSA 患者的氣道壓力,通常需要更高程度的支撐。在這種情況下,醫生可能會提案聯合治療或替代療法,如 CPAP、BiPAP 甚至手術,從而限制獨立口腔器械的市場成長。
未確診的睡眠呼吸中止症病例增加
隨著阻塞型睡眠呼吸中止症(OSA)的盛行率在全球範圍內不斷上升,治療睡眠呼吸中止症的口腔器具市場可能會成長。研究表明,數百萬人未被診斷出來,許多患有睡眠呼吸中止症的人甚至不知道自己患有這種疾病。由於政府、私人醫療機構和衛生組織的宣傳活動不斷加強,診斷率逐漸上升,治療需求也逐漸增加。此外,由於睡眠呼吸中止症通常與肥胖、糖尿病、心血管疾病和高血壓等疾病有關,這些合併症的盛行率不斷上升,預計將推動對口腔器具和其他有效的 OSA 管理解決方案的需求。
來自手術和 CPAP 介入的激烈競爭
CPAP(持續性呼吸道正壓通氣)設備是治療中度至重度阻塞型睡眠呼吸中止症(OSA)的黃金標準,在睡眠呼吸中止口腔器械市場上競爭激烈。 CPAP 設備之所以經常被推薦,是因為它們具有即使在患者不遵醫囑的情況下也能保持氣道暢通的能力。下顎前移術 (MMA)、舌下神經刺激術、腭咽成形術 (UPPP) 等外科手術也越來越受歡迎,尤其是在尋求長期治療方法的患者中。此外,隨著技術進步提高了 CPAP 的舒適度、手術成功率並限制了口腔器械成長的潛力,患者可能更有可能選擇這些方案。
COVID-19 疫情以多種方式影響了睡眠呼吸中止症口腔器械市場,既帶來機會,也帶來挑戰。新口腔器械配件最初的下降是由於供應鏈中斷、製造業放緩以及患者到牙科診所和睡眠中心的就診次數減少。市場限制、醫療機構關閉和封鎖導致許多睡眠呼吸中止症患者推遲治療,阻礙了市場擴張。但這場大流行也提高了人們對呼吸健康和睡眠問題的認知,導致遠端醫療諮詢和在家睡眠測試的增加。此外,我們也向一些患者提出了考慮口腔器械治療作為 CPAP替代的想法,特別是考慮到人們擔心 CPAP 機器可能會將呼吸道飛沫霧化。
預計下顎前移器具市場在預測期內將佔據最大佔有率
預計下顎前牽引裝置將在預測期內佔據最大的市場佔有率,因為它們應用廣泛、效果顯著,並且相對於其他牙科器械更受患者青睞。輕度至中度阻塞型睡眠呼吸中止症(OSA) 可以透過 MAD 有效治療,MAD 透過將下顎略微向前移動來防止睡眠期間氣道崩壞。與舌頭穩定裝置 (TSD) 等替代品相比,這些裝置更舒適,並且保證按照牙醫或牙齒矯正醫師的規定使用。此外,其非侵入性、易於使用以及作為 CPAP 療法替代品的日益普及使其在市場上佔據優勢。
預計預測期內家庭護理環境部分將實現最高的複合年成長率。
由於人們對睡眠呼吸中止症管理認知的不斷提高、對家庭治療選擇的偏好增加以及遠端醫療的進步,預計家庭治療環境部分將在預測期內見證最高的成長率。為了避免頻繁就醫,患者擴大尋求舒適、實惠且可在家中使用的非侵入性解決方案。居家睡眠測試(HST)的使用增加正推動需求,因為它有助於快速診斷和更早開始口腔器械治療。此外,為了進一步促進這個市場,保險公司也在擴大家庭睡眠呼吸中止症治療的覆蓋範圍。
預計預測期內北美地區將佔據最大的市場佔有率。這是由強大的醫療保健體系、高度的認知和不斷上升的睡眠呼吸中止症盛行率所推動的。美國佔據市場主導地位,隨著篩檢、人口老化和肥胖率上升,美國的肥胖病例診斷數量不斷增加。最先進的牙科設備、主要市場參與企業的強大影響力以及優惠的報銷政策進一步加速了其應用。此外,美國睡眠醫學學會 (AASM) 和其他監管機構積極推廣口腔器械療法作為治療方法的可行替代方案,從而提高了患者和醫療保健專業人員對該治療的接受度。
預計預測期內亞太地區將呈現最高的複合年成長率。這現象的發生正值肥胖相關睡眠呼吸中止症盛行率不斷上升、醫療成本不斷上升以及人們對睡眠障礙的認知不斷提高。生活方式的改變、都市化和壓力水平的增加導致中國、印度和日本等國家的睡眠呼吸中止症診斷數量增加。這導致對非侵入性和有效治療方案的需求增加。此外,家庭睡眠測試 (HST) 的採用、保險覆蓋範圍的擴大和醫療保健基礎設施的改善正在推動市場成長。國際牙科和睡眠護理品牌在該地區越來越普及,3D 列印和自訂口腔器具的發展也有助於降低治療費用。
According to Stratistics MRC, the Global Sleep Apnea Oral Appliances Market is accounted for $854.95 million in 2024 and is expected to reach $2343.41 million by 2030 growing at a CAGR of 18.3% during the forecast period. Sleep apnea oral appliances are custom-fitted dental devices designed to treat obstructive sleep apnea (OSA) by repositioning the lower jaw and tongue to keep the airway open during sleep. These devices, sometimes referred to as tongue-retaining devices (TRDs) or mandibular advancement devices (MADs), facilitate better breathing patterns overall, lessen snoring, and lessen airway collapse. Patients with mild to moderate OSA or those who have trouble adhering to CPAP therapy often choose them because they are a non-invasive substitute for CPAP therapy.
According to a study published in the Journal of Clinical Sleep Medicine, oral appliance therapy (OAT) significantly reduced the apnea-hypopnea index (AHI) by an average of 12 events per hour, improving sleep quality for patients with obstructive sleep apnea (OSA).
Increased sleep apnea prevalence
The market for sleep apnea oral appliances is driven in large part by the rising prevalence of sleep apnea, especially obstructive sleep apnea (OSA), which is caused by factors like rising obesity rates, sedentary lifestyles, smoking, alcohol consumption, and an aging population. Additionally, research shows that a significant number of sleep apnea cases go undiagnosed, which can result in serious health complications like diabetes, cardiovascular diseases, and cognitive impairment. As healthcare systems around the world emphasize early detection and treatment of sleep disorders, the demand for oral appliances are expected to increase as a practical and efficient way to manage mild to moderate OSA.
Limited effectiveness in cases of severe sleep apnea
Oral appliances limited ability to treat severe obstructive sleep apnea (OSA) is one of the main factors limiting the market for these devices. In mild to moderate cases, oral appliances are commonly advised; however, in severe cases, where continuous positive airway pressure (CPAP) therapy is still the gold standard, their effectiveness drastically decreases. Furthermore, oral appliances may not be sufficient to support severe OSA patients' airway pressure, which frequently calls for higher levels of support. In these situations, medical practitioners are more likely to suggest combination therapies, alternative treatments like CPAP, BiPAP, or even surgery, which limits the market expansion for standalone oral appliances.
Growing number of sleep apnea cases without a diagnosis
The market for sleep apnea oral appliances has a great chance to grow due to the rising incidence of obstructive sleep apnea (OSA) worldwide. According to studies, millions of people go undiagnosed, and many people with sleep apnea are unaware that they have the condition. Growing awareness campaigns by governments, private healthcare facilities, and health organizations are progressively raising diagnosis rates, which raises the need for treatment. Moreover, because sleep apnea is frequently associated with diseases like obesity, diabetes, cardiovascular disorders, and hypertension, the growing prevalence of these comorbidities is anticipated to increase demand for oral appliances and other efficient OSA management solutions.
Tough competition from surgical and CPAP interventions
Continuous Positive Airway Pressure (CPAP) devices, the gold standard for treating moderate to severe obstructive sleep apnea (OSA), are a fierce competitor in the sleep apnea oral appliances market. CPAP machines are frequently prescribed because of their demonstrated ability to keep the airway open, even in the face of patient noncompliance. Surgical procedures like maxillomandibular advancement (MMA), hypoglossal nerve stimulation, and uvulopalatopharyngoplasty (UPPP) are also becoming more and more common, especially among patients looking for a long-term cure for their ailment. Additionally, patients may choose these alternatives as technology advances increase CPAP comfort and surgical success rates, which would restrict the potential for oral appliance growth.
The COVID-19 pandemic shaped the sleep apnea oral appliances market in a number of ways, including opportunities and challenges. The initial decline in new oral appliance fittings was caused by supply chain disruptions, manufacturing slowdowns, and fewer patients visiting dental clinics and sleep centers. Financial restraints, healthcare facility closures, and lockdowns caused many sleep apnea patients to put off their treatments, which hindered market expansion. But the pandemic also raised awareness of respiratory health and sleep issues, which resulted in more telemedicine consultations and home-based sleep tests. Furthermore, this gave some patients the idea to look into oral appliance therapy as a substitute for CPAP, particularly in light of worries that CPAP devices might aerosolize respiratory droplets.
The Mandibular Advancement Devices segment is expected to be the largest during the forecast period
The Mandibular Advancement Devices segment is expected to account for the largest market share during the forecast period because it is widely used, very effective, and preferred by patients over other dental appliances. Mild to moderate obstructive sleep apnea (OSA) can be effectively treated with MADs because they prevent airway collapse during sleep by moving the mandible, or lower jaw, slightly forward. Compared to alternatives such as Tongue Stabilizing Devices (TSDs), these devices are more comfortable and guaranteed to be used as prescribed by dentists or orthodontists. Moreover, they have established their dominance in the market owing to their non-invasiveness, simplicity of use, and increasing popularity as a substitute for CPAP therapy.
The Home Care Settings segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Home Care Settings segment is predicted to witness the highest growth rate because of the growing awareness of managing sleep apnea, the growing preference for at-home treatment options, and the advancements in telemedicine. In order to avoid frequent clinical visits, patients are increasingly looking for comfortable, affordable, and non-invasive solutions that they can use at home. The increasing use of home sleep testing (HST) has increased demand by facilitating speedier diagnosis and early oral appliance therapy initiation. Furthermore, to further boost this market, insurance companies are also increasing coverage for treatments for sleep apnea that can be done at home.
During the forecast period, the North America region is expected to hold the largest market share, fuelled by a strong healthcare system, a high level of awareness, and the rising incidence of sleep apnea. The market is dominated by the United States, where more cases are being diagnosed as a result of improved screening techniques, aging populations, and rising obesity rates. Adoption has been further accelerated by the availability of cutting-edge dental appliances, the robust presence of important market participants, and advantageous reimbursement policies. Moreover, oral appliance therapy is also actively promoted by the American Academy of Sleep Medicine (AASM) and other regulatory organizations as a viable substitute for CPAP, which increases patient and healthcare provider acceptance of the treatment.
Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by a growing prevalence of obesity-related sleep apnea, rising healthcare costs, and growing awareness of sleep disorders. Due to shifting lifestyles, urbanization, and increased stress levels, sleep apnea diagnoses are on the rise in nations like China, India, and Japan. This has increased demand for non-invasive and efficient treatment options. Additionally, the market is also growing faster due to the adoption of home sleep testing (HST), increased insurance coverage, and better healthcare infrastructure. International dental and sleep therapy brands are becoming more widely available in the area, and developments in 3D-printed and custom-fitted oral appliances are also helping to make treatment more affordable.
Key players in the market
Some of the key players in Sleep Apnea Oral Appliances market include Thermo Fisher Scientific Inc., Zephyr Sleep Technologies, Dentsply Sirona Inc, Fisher & Paykel Healthcare Limited, Airway Management, Inc., Koninklijke Philips N.V, BMC Medical Co., Ltd., DynaFlex Inc, ProSomnus, Inc., Straumann Group, SICAT GmbH and Co. KG, Myerson Solicitors LLP, Apnea Sciences Inc, SomnoMed Inc and ResMed Inc.
In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.
In July 2023, ResMed announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. Somnoware software streamlines the processes of physicians as well as sleep and pulmonary function testing labs for diagnosing and evaluating a patient's sleep and respiratory care test results, ordering PAP treatment equipment, setting up appointments, tracking PAP compliance, and electronically providing this information directly into a patient's electronic health record - all from within the Somnoware platform.
In July 2022, Straumann Group Acquires a Strategic Minority Stake and is Partnering with CareStack to Offer United States Dental Practices an Integrated, All-in-One Practice Management Solution. As a result of this partnership, CareStack will expand its service offering and presence in the United States market and beyond. Working closely with practitioners around the world, CareStack has developed a streamlined digital practice solution for the modern, growth-ready dental practice.